LinusBio

It’s been a little over a month since we launched ClearStrand-ASD, and the excitement hasn’t faded. I’m proud to say that we have delivered our first results to the families who enrolled for our test. Helping families in the way we do is one of the greatest privileges of our work here at LinusBio. As we continue this journey, I wanted to take a moment to share a few insights and highlight some key points worth discussing>>>

It’s been a little over a month since we launched ClearStrand-ASD, and the excitement hasn’t faded. I’m proud to say that we have delivered our first results to the families who enrolled for our test. Helping families in the way we do is one of the greatest privileges of our work here at LinusBio. As we continue this journey, I wanted to take a moment to share a few insights and highlight some key points worth discussing>>>

For too long, precision medicine has focused primarily on genomics—but DNA alone doesn’t tell the whole story. If it did, identical twins would always share the same health outcomes. The current biomarker landscape remains deeply rooted in genomic sequencing, yet this is like going to a gallery and only looking at the frames, ignoring the masterpieces within. Health is shaped by a complex interplay between genes and environment. Now, advances in temporal biomarkers and AI-driven analysis are finally allowing us to capture these influences, offering new hope for conditions like autism, ALS, and Alzheimer’s. By integrating environmental data with genomics, we can unlock a more complete view of human health—and bring true precision to precision medicine. Read my full article on Genetic Engineering & Biotechnology News>> https://lnkd.in/een73Dh5 #PrecisionMedicine #Biomarkers #Innovation #Healthcare #AI

Proud to be part of IBDigital, a groundbreaking initiative revolutionizing IBD management with novel biomarkers! Excited to collaborate with leading experts to drive patient-centric innovation. #IBDigital #DigitalHealth #IBD

LinusBio and Frontera share a mission to support families navigating the challenging journey to an autism diagnosis. By leveraging cutting-edge technology and pioneering objective biomarkers, we aim to transform the autism diagnosis and treatment landscape. We’re proud to partner with Frontera to make this breakthrough technology more accessible. For information on additional financial support programs, contact LinusBio’s customer care team at support@linusbio.com.

Congratulations to LinusBio for developing ClearStrand-ASD, the first early autism biomarker test! By analysing a single strand of hair this innovative and non-invasive test can detect autism risk in infants as young as one month old. In addition to enabling earlier identification of autism in young children to facilitate early intervention, we are hopeful that having a reliable biomarker will be a useful #research tool for developing better, more targeted and personalised #therapeutics to benefit older children and adults with autism. #autism #biomarkers #clinicaltrials #earlyintervention #autismspectrumdisorder

Today, I’m incredibly proud to announce the launch of our first commercial product: ClearStrand-ASD, the first and only objective laboratory test for autism, validated for children as young as 1 month to 36 months old, using just a single strand of hair. For too long, families have faced exhausting, years-long journeys to secure an autism diagnosis. This is what we aim to change. With ClearStrand-ASD, caregivers and clinicians now have access to an objective, science-backed tool that may help facilitate earlier diagnosis and intervention—at the stage when it matters most. This milestone wouldn’t have been possible without the dedication of so many. From the incredible researchers and clinicians who spent over 20 years developing this breakthrough with me, to the families and autism specialists who helped us address real needs, to my partners and mentors on the LinusBio board— Ashok Krishnamurthi, Rafi Syed, and Amol Deshpande—and, of course, to my phenomenal team at LinusBio—thank you. You made this happen. We’re just getting started. Read our exclusive coverage: NBC News➡️ https://lnkd.in/gMKVnPsh Inside Precision Medicine➡️ https://lnkd.in/gWBKzhSX Visit our website ➡️ https://lnkd.in/gZstP42z

🚀 Introducing ClearStrand-ASD: A Novel Autism Biomarker Test 🚀 We’re extremely proud to announce the launch of ClearStrand-ASD –a ground-breaking, first-of-its kind biomarker test that provides biochemical insights about autism as early as one month of age—using just a single strand of hair! ClearStrand-ASD is intended to help physicians rule out autism in children between one and 36 months of age when autism is a concern. The test demonstrated a negative predictive value (NPV) of 92.5% and can help providers identify children who are unlikely to be on the autism spectrum. Dr. Manish Arora, LinusBio’s Founder and CEO: “Families today often endure exhausting journeys to secure a diagnosis for their child, and this is what we aim to change. Caregivers now have access to an objective autism biomarker test that, in collaboration with their health care providers, may help them plan the next steps for their child earlier than ever before.” This is a major step forward for children and their families when autism is a concern —bringing science, precision, and earlier insights to the forefront. Read our exclusive coverage now on NBC News ➡️ https://lnkd.in/dkQ5EPrU Visit the ClearStrand-ASD website ➡️ https://lnkd.in/d_i5YnH3 #biomarker #autism #PrecisionMedicine #EarlyIntervention #ClearStrandASD #HealthcareInnovation The test is performed by the LinusBio laboratory (CLIA #31d2307499) and has not been cleared or approved by the U.S. Food & Drug Administration (FDA).

"Our genes are static, whereas our exposome changes all the time. So how do we map something that is constantly dynamic?" LinusBio's CEO, Dr. Manish Arora, talks with Karen Jagoda about harnessing the exposome to generate novel biomarkers. https://lnkd.in/eKYUw54k #LinusBio #Exposome #Biomarkers #Autism #AutismSpectrumDisorder #AutismBiomarker #ADHD #ALS #Metabolism #MedTech 

Innovative. Transformative. Pioneering. Big news is on the horizon; stay tuned! #ASD #Biomarker